Pfizer Oncology Biosimilars’ Falling ASPs

Pfizer's trastuzumab and rituximab biosimilars have seen dramatic average sales price reductions, reaching up to 93% lower than competitors. Trazimera and Ruxience pricing dropped significantly, despite maintaining notable market shares in their categories. Additionally, Xbrane Biopharma received FDA approval for its ranibizumab biosimilar, Lucamzi, enhancing market competition.